Schizophrenia Research
Volume 98, Issue 1 , Pages 8-15 , January 2008

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia

  • C. Daniel Mullins

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 410 706 0879; fax: +1 410 706 5394.
    • ,
  • Nour A. Obeidat

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • ,
  • Brian J. Cuffel

      Affiliations

    • Pfizer Inc, New York NY, United States
    • ,
  • John Naradzay

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • ,
  • Antony D. Loebel

      Affiliations

    • Pfizer Inc, New York NY, United States

Received 15 November 2006 ,Revised 25 April 2007 ,Accepted 26 April 2007.

References 

  1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601
  2. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin. Ther. 2005;27(2):263–272
  3. Gilbody SM, Bagnall AM, Duggan L, et al. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. 2000;3:(CD002306)
  4. Jaffe AB, Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J. Clin. Psychiatry. 2003;64(Suppl 17):3–6
  5. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J. Clin. Psychiatry. 2003;64(11):1308–1315
  6. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch. Gen. Psychiatry. 2005;62(12):1305–1312
  7. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br. J. Psychiatry. 2004;184:509–516
  8. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am. J. Psychiatry. 2002;159(4):567–572
  9. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry. 2002;63(10):892–909
  10. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353(12):1209–1223
  11. Lung C, Loebel AD, Lombardo ID, et al. Treatment Persistence and Antipsychotic Therapy: Results of a Longitudinal Pharmacy Claims Database Analysis. In: Poster presented at the annual meeting of the American Psychiatric Association, Toronto, Canada. 2006;May
  12. Mallinger JB, Fisher SG, Brown T, et al. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr. Serv. 2006;57(1):133–136
  13. Naber D, Vita A. Tools for measuring clinical effectiveness. Eur. Neuropsychopharmacol. 2004;14(Suppl 4):S435–S444
  14. Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am. J. Epidemiol. 1996;143(10):1059–1068
  15. Opolka JL, Rascati KL, Brown CM, et al. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr. Serv. 2004;55(2):151–156
  16. Pelagotti F, Santarlasci B, Vacca F, et al. Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur. J. Clin. Pharmacol. 2004;59(12):905–909
  17. Santarlasci B, Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann. Pharmacother. 2003;37(4):556–563
  18. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am. J. Manag. Care. 2005;11(7):449–457
  19. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. 1997;50(1):105–116
  20. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry. 2006;163(4):611–622
  21. Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am. J. Psychiatry. 1995;152(12):1749–1756
  22. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr. Serv. 2001;52(6):805–811
  23. Tamminga CA. Practical treatment information for schizophrenia. Am. J. Psychiatry. 2006;163(4):563–565
  24. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv. 2003;54(4):508–516
  25. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 1995;21(3):419–429
  26. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv. 2004;55(8):886–891

PII: S0920-9964(07)00191-0

doi: 10.1016/j.schres.2007.04.035

Schizophrenia Research
Volume 98, Issue 1 , Pages 8-15 , January 2008

Article Tools

* Image Usage & Resolution